Uterine (Endometrial) Cancer Treatment in India
India's gynaecologic oncology teams provide complete endometrial cancer management from robotic hysterectomy and sentinel lymph node biopsy to adjuvant radiation (IMRT + brachytherapy) and Pembrolizumab for MSI-H/MMR-deficient tumours.
Get a Free Treatment Plan in 48 Hours
Send your reports — our specialists will review and send a personalised treatment plan and cost estimate.
📋 Get Free ConsultationSigns & Symptoms of Uterine Cancer
- Unusual vaginal bleeding after menopause
- Abnormal menstrual periods
- Watery or blood-tinged discharge
- Pelvic pain or pressure
- Difficulty urinating
Treatment Options Available in India
- Total laparoscopic/robotic hysterectomy + BSO
- Pelvic and para-aortic lymph node dissection
- Sentinel lymph node mapping
- Vaginal brachytherapy
- External beam IMRT
- Carboplatin + Paclitaxel chemotherapy
- Pembrolizumab + Carboplatin/Paclitaxel (MSI-H)
- Progestin therapy (low-grade, fertility-sparing)
Why Treat Uterine Cancer in India?
India offers world-class cancer care at a fraction of Western costs, with no compromise on quality or outcomes.
| Cost Comparison | India | USA |
|---|---|---|
| Uterine Cancer Treatment (total) | $4,000–$12,000 | $30,000–$100,000 |
| Savings with India | 60–80% less than USA | |
Best Hospitals
- Tata Memorial Hospital, Mumbai
- Apollo Cancer Centre, Chennai
- Medanta — The Medicity, Gurugram
- Fortis Memorial Research Institute, Gurugram
- Max Super Speciality Hospital, Delhi
Key Facts
- Stage I/II endometrial cancer has 85–95% cure rates with surgery ± radiation
- MSI-H/dMMR testing available for immunotherapy eligibility within 5 days
- Robotic hysterectomy for endometrial cancer costs $5,000–$8,000 vs $30,000–$50,000 in USA
- Fertility-sparing management available for Grade 1, Stage IA endometrial cancer
Frequently Asked Questions
Q: What is the success rate of uterine cancer treatment in India?
A: Stage I endometrial cancer has 85–95% 5-year survival with surgery ± radiation at India's top centres. Stage II achieves 70–80%. Stage III/IV is treated with chemotherapy + immunotherapy, achieving 40–60% 5-year survival in MSI-H tumours.